Sepracor Inc. Reports Second Quarter 2008 Results Business Wire (press release), CA - SEP-225289, a novel triple reuptake inhibitor for the treatment of depression, is well-advanced in a Phase II proof-of-concept study with clinical results ... |
Tuesday, July 29, 2008
Sepracor Inc. Reports Second Quarter 2008 Results - Business Wire (press release)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment